David L. Lacey's most recent trade in Arcus Biosciences Inc was a trade of 16,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 16,900 | 16,900 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 5,700 | 76,652 (0%) | 0% | 0 | Common Stock | |
| Nurix Therapeutics Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2026 | 31,250 | 31,250 | - | - | Director Stock Option (right to buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 38,300 | 38,300 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 13,300 | 70,952 (0%) | 0% | 0 | Common Stock | |
| Nurix Therapeutics Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 8,400 | 57,652 (0%) | 0% | 0 | Common Stock | |
| Nurix Therapeutics Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 19,500 | 19,500 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 6,800 | 49,252 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc Ordinary Shares | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Nurix Therapeutics Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,800 | 16,800 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 4,100 | 42,452 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc Ordinary Shares | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Nurix Therapeutics Inc | David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 17,500 | 17,500 | - | - | Director Stock Option (right to buy) |